Callan Capital LLC Has $3.57 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Callan Capital LLC lifted its stake in Eli Lilly and Company (NYSE:LLY) by 15.7% in the second quarter, HoldingsChannel reports. The firm owned 3,943 shares of the company’s stock after purchasing an additional 536 shares during the period. Callan Capital LLC’s holdings in Eli Lilly and Company were worth $3,570,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. AMJ Financial Wealth Management purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth approximately $201,000. Aveo Capital Partners LLC boosted its stake in shares of Eli Lilly and Company by 8.2% during the 4th quarter. Aveo Capital Partners LLC now owns 2,020 shares of the company’s stock valued at $1,178,000 after buying an additional 153 shares during the period. Gryphon Financial Partners LLC grew its holdings in shares of Eli Lilly and Company by 19.4% during the 4th quarter. Gryphon Financial Partners LLC now owns 2,324 shares of the company’s stock valued at $1,355,000 after acquiring an additional 377 shares in the last quarter. Quest Partners LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter worth $313,000. Finally, GW&K Investment Management LLC grew its stake in Eli Lilly and Company by 2.4% in the fourth quarter. GW&K Investment Management LLC now owns 754 shares of the company’s stock valued at $440,000 after purchasing an additional 18 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 1,441 shares of Eli Lilly and Company stock in a transaction on Friday, June 28th. The shares were sold at an average price of $915.02, for a total transaction of $1,318,543.82. Following the completion of the sale, the insider now owns 97,367,369 shares of the company’s stock, valued at approximately $89,093,089,982.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 442,229 shares of company stock valued at $410,002,456 over the last ninety days. Insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on LLY. Berenberg Bank lifted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday. Jefferies Financial Group raised their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday, June 24th. BMO Capital Markets upped their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Finally, Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $977.35.

Eli Lilly and Company Price Performance

LLY opened at $915.04 on Friday. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The company’s 50 day simple moving average is $895.62 and its 200-day simple moving average is $836.99. Eli Lilly and Company has a one year low of $516.57 and a one year high of $972.53. The stock has a market capitalization of $869.66 billion, a P/E ratio of 134.76, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The company had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. Sell-side analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.57%. The ex-dividend date of this dividend was Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is 76.58%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.